- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00623597
A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.
February 4, 2016 updated by: Hoffmann-La Roche
A Phase I/II Study of Invirase® Boosted With Ritonavir in HIV Infected Infants and Children 4 Months to Less Than 6 Years Old
This single arm study will assess the pharmacokinetics, safety and activity of saquinavir (Invirase hard gel capsules, film coated tablets or opened capsules) boosted by combination with ritonavir, in HIV-1 infected infants and children between the ages of 4 months and 6 years.
Patients will commence treatment with saquinavir 50mg/kg bid plus ritonavir 2.5mg/kg or 3.0mg/kg (dependent on body weight), and a background antiretroviral regimen.
If drug exposures are found to be dissimilar to those previously seen in older children and adults, or are associated with toxicities, subsequent dose adjustments will be made.
The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 months to 6 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- infants and children, 4 months to <6 years;
- confirmed HIV-1 infection;
- patients for whom saquinavir/ritonavir together with >=2 background ARVs is considered appropriate.
Exclusion Criteria:
- body weight >4kg/8.8 pounds;
- use of any concomitant medications that may interfere with the pharmacokinetics of saquinavir or ritonavir;
- malabsorption, severe chronic diarrhea or vomiting within 28 days of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
2.5-3.0mg/kg
po bid (starting dose) for 48 weeks
50mg/kg po bid (starting dose) for 48 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Trough Concentrations (Ctrough) for Saquinavir
Time Frame: Pre-dose at Weeks 8, 12, 24.
|
Plasma trough concentration is the average steady state concentration prior to morning and evening dose.
Ctrough of Saquinavir was normalized to a dose of 50 mg/kg.
|
Pre-dose at Weeks 8, 12, 24.
|
Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Saquinavir
Time Frame: Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an Non-nucleoside reverse transcriptase inhibitor [NNRTI] containing regimen).
|
The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast.
The area under the plasma concentration-time curve from time zero to twelve hours of saquinavir was normalized to a dose of 50 mg/kg.
|
Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an Non-nucleoside reverse transcriptase inhibitor [NNRTI] containing regimen).
|
Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)
Time Frame: From Baseline (Day 1) till Week 48 and Follow-up (Week 52)
|
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes
|
From Baseline (Day 1) till Week 48 and Follow-up (Week 52)
|
Change In Hematocrit From Baseline
Time Frame: Baseline (Day 1), Week 24 and Week 48
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline (Day 1), Week 24 and Week 48
|
Change In Hemoglobin, Total Protein And Total Albumin From Baseline
Time Frame: Baseline (Day 1), Week 24 and Week 48
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline (Day 1), Week 24 and Week 48
|
Change In White Blood Cell (WBC), Platelet, Basophil, Lymphocyte, Monocyte, Neutrophil And Eosinophil Cell Counts From Baseline
Time Frame: Baseline (Day 1), Week 24 and Week 48
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline (Day 1), Week 24 and Week 48
|
Change In Red Blood Cell (RBC) Counts From Baseline
Time Frame: Baseline (Day 1), Week 24 and Week 48
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline (Day 1), Week 24 and Week 48
|
Change In Creatine Kinase (CK), Serum Glutamic Oxaloacetic Transaminase (SGOT), Alkaline Phosphatase (ALP), Serum Glutamic-Pyruvic Transaminase (SGPT), Gamma-Glutamyl Transferase (GGT) Counts From Baseline
Time Frame: Baseline (Day 1), Week 24 and Week 48
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline (Day 1), Week 24 and Week 48
|
Change In Total Bilirubin, Creatinine, Uric Acid From Baseline
Time Frame: Baseline (Day 1), Week 24 and Week 48
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline (Day 1), Week 24 and Week 48
|
Change In Blood Urea Nitrogen (BUN), Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL Cholesterol), Triglycerides, Calcium, Potassium, Sodium, Chloride, Phosphate, Fasting Glucose From Baseline
Time Frame: Baseline (Day 1), Week 24 and Week 48
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline (Day 1), Week 24 and Week 48
|
Change In Hematuria, Glycosuria And Proteinuria From Baseline
Time Frame: Baseline (Day 1), Week 24 and Week 48
|
Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
|
Baseline (Day 1), Week 24 and Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Trough Concentrations (Ctrough) for Ritonavir
Time Frame: Pre-dose at Weeks 8, 12, 24
|
Plasma trough concentration is the average steady state concentration prior to morning and evening dose.
Ctrough of Ritonavir was normalized to a dose of 100 mg/kg.
|
Pre-dose at Weeks 8, 12, 24
|
Maximum Observed Concentration (Cmax) for Saquinavir and Ritonavir
Time Frame: Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen and at Week 24
|
The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.
Cmax was normalized to a dose of 50 mg/kg for Saquinavir and100 mg/kg for Ritonavir.
|
Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen and at Week 24
|
Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Ritonavir
Time Frame: Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen).
|
The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast.
The area under the plasma concentration-time curve from time zero to twelve hours of ritonasvir was normalized to a dose of 100 mg/kg.
|
Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen).
|
Change From Baseline in Mean Human Immunodeficiency Virus Viral Load
Time Frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
|
Change from baseline in plasma HIV-1 RNA was derived as Change from baseline = Log10 (HIV-1 RNA at week x) - Log10 (HIV-1 RNA at baseline)
|
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
|
Number of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <400 Copies/mL
Time Frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
|
The number of participants with HIV-1 RNA results <400 copies/mL were reported
|
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
|
Number of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <50 Copies/mL
Time Frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
|
The number of participants with HIV-1 RNA results <50 copies/mL were reported.
|
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
|
Number of Participants With >1 Log Decrease From Baseline in Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA )
Time Frame: From Week 8 till Week 48
|
The number of participants experiencing a greater than 1 log drop from baseline (day 1) (log 10 transformed) were reported
|
From Week 8 till Week 48
|
Number of Participants With Virological Failure
Time Frame: From Week 12 till Week 48
|
Virological failure was defined as: viral load >= 400 copies/mL on two consecutive occasions (missing visits was assumed to be above 400 copies/mL).
The number of participants classified as virological failure by Age Group and viral load (≤ 10,000 copies, >10,000 copies) were presented.
|
From Week 12 till Week 48
|
Change From Baseline in Cluster Differentiation Antigen 4 (CD4) Lymphocyte Count
Time Frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation
|
Change from Baseline in CD4+ lymphocyte count at 24 weeks and 48 weeks were presented by age group.
Change from baseline in CD4+ lymphocyte count was derived as follows: Change from baseline = (CD4+ count at week 24/48) - (CD4+ count at baseline).
A baseline collection was made if there was not already a value available taken within the previous 4 weeks.
Baseline was on Day 1.
|
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation
|
Change From Baseline in Cluster Differentiation Antigen 8 (CD8) Lymphocyte Count
Time Frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation
|
Change from baseline in CD8+ lymphocyte count at 24 weeks and 48 weeks were presented by age group.
Change from baseline in CD8+ lymphocyte count was derived as follows: Change from baseline = (CD8+ count at week 24/48) - (CD8+ count at baseline).
A baseline collection was made if there was not already a value available taken within the previous 4 weeks.
Baseline was on Day 1.
|
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
March 1, 2010
Study Completion (Actual)
March 1, 2010
Study Registration Dates
First Submitted
February 18, 2008
First Submitted That Met QC Criteria
February 18, 2008
First Posted (Estimate)
February 26, 2008
Study Record Updates
Last Update Posted (Estimate)
March 7, 2016
Last Update Submitted That Met QC Criteria
February 4, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Ritonavir
- Saquinavir
Other Study ID Numbers
- NV20911
- 2007-004617-34
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on ritonavir
-
PfizerNot yet recruitingHealthy Participants | Biological Availability
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Completed
-
Karolinska InstitutetKarolinska University Hospital; PfizerRecruitingCOVID-19 | Post-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | POTS - Postural Orthostatic Tachycardia Syndrome | Postinfectious Inflammation | Postinfectious DisorderSweden
-
Drugs for Neglected DiseasesUniversity of Cape Town; Medecins Sans Frontieres, Netherlands; UBS Optimus Foundation and other collaboratorsCompletedAcquired Immunodeficiency Syndrome | TuberculosisSouth Africa
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Recruiting
-
Fujian Akeylink Biotechnology Co., Ltd.Active, not recruitingCOVID-19 Respiratory InfectionChina
-
Qilu Pharmaceutical Co., Ltd.Recruiting
-
The HIV Netherlands Australia Thailand Research...Ministry of Education, ThailandCompletedHIV Infections | HIV InfectionThailand
-
PfizerCompletedHealthy ParticipantsBelgium